IFNAR2 and COVID-19: To gain insight into this double-edged impact of IFNAR2 variation on COVID-19, we examined transcriptomic data of PBMCs at the peak of infection at the time of hospitalization and consistently with biomarker data, we observed that the p.F8S variant was associated with enhanced activation of immune pathways and anti-viral responses.